Enzymatica has developed ColdZyme, a mouth spray that shortens the duration of colds and relieves symptoms such as sore throats. The product is sold in Sweden and the UK through contract organizations and through partner agreements in other markets.
Strong start to the year with increased sales
Enzymatica's first quarter report shows that total net sales amounted to SEK 12,3 million during the first quarter, which corresponds to an increase of 30,3 percent compared to the same period in 2024 when sales were SEK 9,4 million.
In Sweden, sales increased by SEK 2,3 million, corresponding to a growth of 31,5 percent compared to the same period last year. According to the company, this is a clear sign that the product is both reaching and appreciated by consumers.
Focus on international collaborations
No sales through partners were reported during the quarter. Therefore, Enzymatica is now focusing on discussions with potential partners to expand ColdZyme's international presence.
– Supported by strong patent protection and new clinical evidence, Enzymatica is in an exciting phase – where we believe in growth opportunities in the international arena, says CEO Claus Egstrand in the report.
The product is CE marked according to the new European Medical Device Regulation (MDR), which enables launch in new European markets as soon as partnership agreements are signed. Outside Europe, regulatory processes are underway that are adapted to the respective market requirements.
Publication of study results during the quarter
The first quarter was also an important period for ColdZyme as study results were published in the medical journal The Journal of Physiology at the end of February. The publication is based on both clinical data and in vitro results from research at the universities of Kent and Vienna.
Both studies showed that ColdZyme effectively reduced viral load. Participants in the clinical study also reported fewer sick days and milder symptoms compared to placebo. Hear from the professors Glen Davison and Doris Wilflingseder tell us more about the results here.
CEO on the path to global expansion
BioStock contacted Enzymatica's CEO Claus Egstrand to learn more about the company's progress during the first quarter and what is needed to establish ColdZyme in more international markets.
The report shows increased sales in Sweden and the UK, but no sales through partners during the quarter. Can you explain what is behind this?
– Partners and potential partners have been waiting for the results of the independent, researcher-initiated study at the University of Kent to be published in a peer-reviewed journal. Publication in a peer-reviewed journal is a requirement for using the study results in marketing in markets such as Germany and the UK. As the publication did not take place until 28 February, discussions about the next steps could only begin thereafter. In addition, there is a production lead time of approximately three months, which means that no partner orders were possible during the first quarter.
Which international markets do you see as most promising for ColdZyme in the future, and why?
– The most immediate opportunities with the scientifically reviewed results are in Europe, where ColdZyme is already certified as a Class III medical device. The European market also offers great potential in terms of market size.
– A natural next step after Europe are markets where the registration process can build on the MDR certification, such as Australia, Japan and parts of the Middle East and Africa. Markets such as the US and Latin America have different regulatory approval frameworks, which can mean longer approval processes. However, in terms of absolute potential, the US is always an attractive market.
– In summary, we have identified a clear regulatory path forward to optimize our market opportunities in a structured manner.
What criteria are most important to Enzymatica when evaluating and selecting new business partners?
– We have always believed in the power of three – that is, the three crucial success factors:
- Critical mass and marketing and sales power in the cold category
- Deeper understanding of the consumer and their needs in the cold area
- A genuine sense of building a true partnership to maximize shared potential
What demands and expectations do potential partners place on Enzymatica and on ColdZyme as a product?
- Quality, quality, quality in everything we do – because it's about their company name and brand
- Strong, scientifically reviewed clinical study data, including prospects for future studies and claims
- A genuine sense of building a true partnership to maximize shared potential
What milestones can we expect from Enzymatica during the rest of 2025?
– We hope to announce agreements for the marketing and sale of ColdZyme with new claims together with both existing and new partners.
